Antidepressive Agents, Second-Generation
"Antidepressive Agents, Second-Generation" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A structurally and mechanistically diverse group of drugs that are not tricyclics or monoamine oxidase inhibitors. The most clinically important appear to act selectively on serotonergic systems, especially by inhibiting serotonin reuptake.
Descriptor ID |
D018687
|
MeSH Number(s) |
D27.505.954.427.700.122.050
|
Concept/Terms |
Antidepressive Agents, Second-Generation- Antidepressive Agents, Second-Generation
- Antidepressive Agents, Second Generation
- Second-Generation Antidepressive Agents
- Agents, Second-Generation Antidepressive
- Second Generation Antidepressive Agents
- Atypical Antidepressants
- Antidepressants, Atypical
- Antidepressive Drugs, Second-Generation
- Antidepressive Drugs, Second Generation
- Drugs, Second-Generation Antidepressive
- Second-Generation Antidepressive Drugs
|
Below are MeSH descriptors whose meaning is more general than "Antidepressive Agents, Second-Generation".
Below are MeSH descriptors whose meaning is more specific than "Antidepressive Agents, Second-Generation".
This graph shows the total number of publications written about "Antidepressive Agents, Second-Generation" by people in this website by year, and whether "Antidepressive Agents, Second-Generation" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2005 | 2 | 0 | 2 |
2006 | 1 | 1 | 2 |
2007 | 0 | 1 | 1 |
2008 | 1 | 0 | 1 |
2009 | 1 | 0 | 1 |
2010 | 1 | 0 | 1 |
2016 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antidepressive Agents, Second-Generation" by people in Profiles.
-
Qaseem A, Barry MJ, Kansagara D. Nonpharmacologic Versus Pharmacologic Treatment of Adult Patients With Major Depressive Disorder: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med. 2016 Mar 01; 164(5):350-9.
-
Abouzaid S, Jutkowitz E, Foley KA, Pizzi LT, Kim E, Bates J. Economic impact of prior authorization policies for atypical antipsychotics in the treatment of schizophrenia. Popul Health Manag. 2010 Oct; 13(5):247-54.
-
Mufti MA, Holtzheimer PE, Epstein CM, Quinn SC, Vito N, McDonald WM. Bupropion decreases resting motor threshold: a case report. Brain Stimul. 2010 Jul; 3(3):177-80.
-
Qaseem A, Snow V, Denberg TD, Forciea MA, Owens DK. Using second-generation antidepressants to treat depressive disorders: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2008 Nov 18; 149(10):725-33.
-
Majewski S, Donnenfeld AE, Kuhlman K, Patel A. Second-trimester prenatal diagnosis of total arhinia. J Ultrasound Med. 2007 Mar; 26(3):391-5.
-
Breza TS, Zheng P, Porcu P, Magro CM. Cutaneous marginal zone B-cell lymphoma in the setting of fluoxetine therapy: a hypothesis regarding pathogenesis based on in vitro suppression of T-cell-proliferative response. J Cutan Pathol. 2006 Jul; 33(7):522-8.
-
Pinninti NR, Mago R. Tardive dystonia-associated prescription of aripiprazole. J Neuropsychiatry Clin Neurosci. 2006; 18(3):426-7.
-
Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH, Skaar T, Storniolo AM, Li L, Araba A, Blanchard R, Nguyen A, Ullmer L, Hayden J, Lemler S, Weinshilboum RM, Rae JM, Hayes DF, Flockhart DA. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst. 2005 Jan 05; 97(1):30-9.
-
Hollander E, Sood E, Pallanti S, Baldini-Rossi N, Baker B. Pharmacological treatments of pathological gambling. J Gambl Stud. 2005; 21(1):99-110.